Semi-Annual Consolidated Statement Of Cash Flows

KAKEN PHARMACEUTIAL CO., LTD. - Filing #7298504

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
19,235,000,000 JPY
5,658,000,000 JPY
Depreciation
1,265,000,000 JPY
1,291,000,000 JPY
Amortization of goodwill
39,000,000 JPY
117,000,000 JPY
Interest and dividend income
-303,000,000 JPY
-255,000,000 JPY
Interest expenses
12,000,000 JPY
8,000,000 JPY
Decrease (increase) in trade receivables
2,692,000,000 JPY
-4,870,000,000 JPY
Decrease (increase) in inventories
304,000,000 JPY
-2,293,000,000 JPY
Increase (decrease) in trade payables
-1,082,000,000 JPY
2,034,000,000 JPY
Other, net
1,110,000,000 JPY
-392,000,000 JPY
Subtotal
23,600,000,000 JPY
1,278,000,000 JPY
Interest and dividends received
301,000,000 JPY
255,000,000 JPY
Interest paid
-12,000,000 JPY
-8,000,000 JPY
Net cash provided by (used in) operating activities
23,932,000,000 JPY
-245,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-1,961,000,000 JPY
-734,000,000 JPY
Purchase of investment securities
-200,000,000 JPY
JPY
Proceeds from sale of investment securities
JPY
8,000,000 JPY
Other, net
-209,000,000 JPY
-228,000,000 JPY
Net cash provided by (used in) investing activities
-2,432,000,000 JPY
-1,141,000,000 JPY
Cash flows from financing activities
Dividends paid
-2,840,000,000 JPY
-2,813,000,000 JPY
Net cash provided by (used in) financing activities
-2,839,000,000 JPY
-2,813,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
JPY
JPY
Net increase (decrease) in cash and cash equivalents
18,661,000,000 JPY
-4,199,000,000 JPY
Cash and cash equivalents
83,987,000,000 JPY
65,325,000,000 JPY
70,060,000,000 JPY
74,260,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.